Bioquell PLC Miscellaneous replacement - Purchase of Own Shares (7651J)

TIDMBQE

RNS Number : 7651J

Bioquell PLC

30 June 2017

30 June 2017

The following replaces the RNS announcement titled "Purchase of own shares" released on 29 June 2017 at 08:59 under RNS Number 5682J.

The figure stated in respect of the number of ordinary shares purchased was incorrect and has been amended below, as well as the resulting treasury shares and total voting rights. The relevant amendments are identified with an asterisk (*). All other details remain unchanged.

Bioquell PLC

("Bioquell", or "the Company")

Purchase of own shares

Further to the Company's announcement on 3 May 2017 stating its intention to reduce its capital by means of purchasing its shares from time to time using existing cash resources, the Company announces that on 28 June 2017 it purchased 30,000* of its ordinary shares on the London Stock Exchange at a price of 165 pence per share. The purchased shares will all be held as treasury shares.

Aggregated information:

 
 Date of purchase:            28 June 2017 
 Number of ordinary shares 
  purchased:                  30,000* 
 Volume weighted average      165 pence 
  price paid per share: 
 
 Transaction details: 
 Issuer name:                 Bioquell Plc 
 ISIN:                        GB0004992003 
 Timezone:                    GMT 
 Currency:                    GBP 
 

Total Number of Voting Rights

In accordance with DTR 5.6.1 of the FCA's Disclosure Guidance and Transparency Rules, the Company is required to notify the market of the total number of voting rights and capital in the Company.

The issued share capital of the Company is comprised of 23,197,457 ordinary shares of 10p each. As 792,000* of these ordinary shares are held as treasury shares, the total number of voting rights in the Company is 22,405,457*. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 
Bioquell PLC                     Tel: [phone] 
                                  835800 
Ian Johnson, Executive Chairman 
Michael Roller, Finance 
 Director 
 
N+1 Singer                       Tel: [phone] 
                                  3000 
 
 

Mark Taylor

James White

This information is provided by RNS

The company news service from the London Stock Exchange

END

POSOKKDNDBKDAAN

(END) Dow Jones Newswires

June 30, 2017 07:48 ET (11:48 GMT)